(2R,4R,6S)-2,4,6-trimethylpiperidine | 23513-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2R,4R,6S)-2,4,6-trimethylpiperidine
• 英文别名: (2R,6S)-2,4,6-trimethylpiperidine
• CAS: 23513-20-4
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: GELXVDNNZSIRQA-IEESLHIDSA-N

物化性质

• 沸点：
  165.5±0.0 °C(Predicted)
• 密度：
  0.783±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• METHOD OF INHIBITING C-KIT KINASE
  申请人：Illig R. Carl

  公开号：US20080051402A1

  公开（公告）日：2008-02-28

  A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明提供了一种减少或抑制细胞或主体中C-KIT激酶活性的方法，以及使用本发明的化合物预防或治疗主体中的细胞增殖障碍和/或与C-KIT相关疾病的应用：或其溶剂化物、水合物、互变异构体或药用可接受盐。本发明进一步涉及治疗癌症和其他细胞增殖障碍等条件的方法。
• [EN] 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL] ET COMPOSÉS ASSOCIÉS UTILISÉS COMME MODULATEURS POUR L'ÉPISSAGE DES ACIDES NUCÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2022006543A1

  公开（公告）日：2022-01-06

  The present disclosure features compounds e.g. of formula (I-a) and similar compounds e.g. of formulae (l-g), (l-i), (l-j), (III), (lll-a), (III- b) and (IV) disclosed herein and other related compounds, and pharmaceutical compositions thereof. The present disclosure further discloses said compounds and their compositions for use in methods of modulating nucleic acid splicing, as well as said compounds for use in methods of treating e.g.: • proliferative diseases, such as e.g. cancer, benign neoplasms or angiogenesis, • neurological diseases or disorders, such as e.g. Huntington's disease, • autoimmune diseases or disorders, immunodeficiency diseases or disorders, lysosomal storage disease or disorder, cardiovascular diseases or disorders, metabolic diseases or disorders, respiratory diseases or disorders, renal diseases or disorders, or infectious diseases. Exemplary compounds are e.g. 5-[5-(piperidin-4-y l)thieno[3,2- c]pyrazol-2-yl]indazole and 5-[2-(piperidin-4-yl)-[1,2,4]triazolo[3,2-b] [1,3]thiazol-5-yl]indazole derivatives and related compounds.

  本公开涉及化合物，例如式(I-a)的化合物以及类似的化合物，例如式(l-g)，(l-i)，(l-j)，(III)，(lll-a)，(III-b)和(IV)以及其他相关化合物及其药物组合物。本公开进一步揭示了所述化合物及其组合物用于调节核酸剪接的方法，以及所述化合物用于治疗的方法，例如： •增殖性疾病，例如癌症、良性肿瘤或血管生成， •神经疾病或障碍，例如亨廷顿病， •自身免疫疾病或障碍，免疫缺陷疾病或障碍，溶酶体贮积病或障碍，心血管疾病或障碍，代谢性疾病或障碍，呼吸系统疾病或障碍，肾脏疾病或障碍，或传染病。示例化合物包括例如5-[5-(哌啶-4-基)噻吩[3,2-c]吡唑-2-基]吲唑和5-[2-(哌啶-4-基)-[1,2,4]三唑噻吩[3,2-b][1,3]噻唑-5-基]吲唑衍生物及相关化合物。
• [EN] 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE ET COMPOSÉS Y RELATIFS EN TANT QUE MODULATEURS POUR L'ÉPISSAGE D'ACIDES NUCLÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRANTES
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2022006550A1

  公开（公告）日：2022-01-06

  The present disclosure features compounds of formula (l-a) and of formula (II) and pharmaceutical compositions thereof. The present disclosure further discloses the compounds of formula (I- a) and (II) and their compositions for use in methods of modulating nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as said compounds for use in methods of treating e.g.: • proliferative diseases, such as e.g. cancer, benign neoplasms or angiogenesis, • neurological diseases or disorders, such as e.g. Huntington's disease, • autoimmune diseases or disorders, immunodeficiency diseases or disorders, lysosomal storage disease or disorder, cardiovascular diseases or disorders, metabolic diseases or disorders, respiratory diseases or disorders, renal diseases or disorders, or infectious diseases. Exemplary compounds are e.g. 2-(indazol-5-yl)-6-(piperidin-4-yl)-l,7- naphthyridine derivatives and similar compounds.

  本公开涉及公式(l-a)和公式(II)的化合物及其药物组合物。本公开还揭示了公式(I-a)和(II)的化合物及其组合物，用于调节核酸剪接的方法，例如，剪接预mRNA，以及用于治疗方法的化合物，例如： •增殖性疾病，如癌症、良性肿瘤或血管生成等， •神经系统疾病或障碍，如亨廷顿病等， •自身免疫性疾病或障碍、免疫缺陷性疾病或障碍、溶酶体贮积病或障碍、心血管疾病或障碍、代谢性疾病或障碍、呼吸系统疾病或障碍、肾脏疾病或障碍或传染性疾病。示例化合物包括2-(吲哚-5-基)-6-(哌啶-4-基)-1,7-萘啶衍生物和类似化合物。
• [EN] BENZODIAZEPINE DERIVATIVES<br/>[FR] DERIVES DE BENZODIAZEPINE
  申请人：MERCK SHARP & DOHME LIMITED

  公开号：WO1994003437A1

  公开（公告）日：1994-02-17

  (EN) Compounds of formula (I), and salts and prodrugs thereof, wherein R1 represents H, optionally substituted C1-6alkyl or C3-7cycloalkyl; R2 is NHR12 or (CH2)sR13 where s is 0, 1 or 2; R3 represents C1-6alkyl, halo or NR6R7; R4 and R5 are H , C1-12alkyl optionally substituted by NR9R9' or an azacyclic or azabicyclic group, optionally substituted C4-9cycloalkyl, C4-9cycloalkylC1-4alkyl, aryl, arylC1-6alkyl or azacyclic or azabicyclic groups, or R4 and R5 together form the residue of an optionally substituted azacyclic or azabicyclic ring system; x is 0, 1, 2 or 3; R12 is optionally substituted phenyl or pyridyl; R13 represents a group (A) wherein R14 is H or C1-6alkyl; R15 is H, C1-6alkyl, halo or NR6R7; and the dotted line is an optional covalent bond; are CCK and/or gastrin antagonists useful in therapy.(FR) L'invention concerne des composés de la formule (I), ainsi que des sels et des promédicaments de ceux-ci, formule dans laquelle R1 représente H, alkyle C1-6 éventuellement substitué ou cycloalkyle C3-7; R2 représente NHR12 ou (CH2)sR13 où S vaut 0, 1 ou 2; R3 représente alkyle C1-6, halo ou NR6R7; R4 et R5 représentent H, alkyle C1-12 éventuellement substitué par NR9R9' ou un groupe azacyclique ou azabicyclique, cycloalkyle C4-9 éventuellement substitué, C4-9cycloalkylC1-4alkyle, aryle, arylC1-6alkyle ou des groupes azacycliques ou azabicycliques, ou R4 et R5 forment ensemble le résidu d'un système azacyclique ou azabicyclique; x vaut 0, 1, 2 ou 3; R12 représente phényle éventuellement substitué ou pyridyle; R13 représente un groupe (A) dans lequel R14 représente H ou alkyle C1-6; R15 représente H, alkyle C1-6, halo ou NR6R7, et la ligne pointillée représente une liaison covalente optionnelle. Ces composés sont des antagonistes de CCK et/ou de la gastrine utilisés en thérapie.

  化合物的化学式为（I），其盐和前药，其中R1代表H，可选取代的C1-6烷基或C3-7环烷基；R2为NHR12或（CH2）sR13，其中s为0、1或2；R3代表C1-6烷基、卤素或NR6R7；R4和R5为H，C1-12烷基，可选取代的NR9R9'或含氮杂环或含氮杂双环基团，可选取代的C4-9环烷基、C4-9环烷基C1-4烷基、芳基、芳基C1-6烷基或含氮杂环或含氮杂双环基团，或R4和R5共同形成一个可选取代的含氮杂环或含氮杂双环的残基；x为0、1、2或3；R12为可选取代的苯基或吡啶基；R13代表一个（A）基团，其中R14为H或C1-6烷基；R15为H、C1-6烷基、卤素或NR6R7；虚线为可选的共价键；它们是治疗中有用的CCK和/或胃泌素拮抗剂。
• [EN] USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER<br/>[FR] UTILISATION D'INHIBITEUR CFMS POUR LE TRAITEMENT OU LA PRÉVENTION DU CANCER DES OS ET DE LA PERTE OSSEUSE ET DE LA DOULEUR OSSEUSE ASSOCIÉES AU CANCER DES OS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009058801A1

  公开（公告）日：2009-05-07

  The present invention provides therapeutic methods for treating a subject having, and prophylactic methods for preventing in a subject at risk of (or susceptible to ) developing, bone cancer and the bone loss and bone pain associtated with bone cancer, said method comprising the administration of a compound of Formula (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

  本发明提供了治疗患有骨癌及预防患有骨癌风险（或易感）的受试者骨损失和骨癌相关骨痛的治疗方法，该方法包括给予化合物I的一种，或其溶剂、水合物、互变异构体或其药学上可接受的盐。